Patents Assigned to APHP
  • Publication number: 20220233673
    Abstract: A method of producing a monomer of a Shiga toxin B-subunit (STxB) protein or of a variant thereof by peptide chemical synthesis, as well as to a method of producing a pentamer of the STxB protein or of the variant thereof. The methods are particularly advantageous as they overcome major issues typically observed in peptide chemical synthesis, including solubility and purity issues.
    Type: Application
    Filed: June 4, 2020
    Publication date: July 28, 2022
    Applicants: INSTITUT CURIE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), COMMISSARIAT Á L'ÉNERGIE ATOMIQUE ET AUX ÉNERGIES ALTERNATIVES (CEA), APHP (ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS), UNIVERSITY OF UTAH RESEARCH FOUNDATION
    Inventors: Anne BILLET, Frédéric SCHMIDT, Ludger JOHANNES, Denis SERVENT, Gilles MOURIER, Éric TARTOUR, Michael KAY, James M. FULCHER
  • Patent number: 11389434
    Abstract: The inventors demonstrate for the first time the activation of the Hedgehog (HH) signaling pathway in normal and abnormal human mast cells (MCs). These results prompt the inventors to explore the consequence of the inhibition of the HH pathway, especially the canonical pathway, on MC proliferation. They demonstrate that Hedgehog inhibitors inhibit proliferation and induces apoptosis of mast cells. Accordingly the present invention relates to a method of treating a mast cell disease in a patient in need there of comprising administering to the patient a therapeutically effective amount of a Hedgehog inhibitor.
    Type: Grant
    Filed: May 17, 2018
    Date of Patent: July 19, 2022
    Assignees: INSERM, FONDATION IMAGINE, UNIVERSITE PARIS DESCARTES, ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (APHP), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: Leila Maouche-Chretien, Christine Bodemer, Olivier Hermine, Laura Polivka
  • Patent number: 11385231
    Abstract: The present invention relates to methods for predicting the survival time of patients suffering from a lung cancer.
    Type: Grant
    Filed: August 26, 2016
    Date of Patent: July 12, 2022
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE SCIENTIFIQUE), UNIVERSITE DE PARIS, SORBONNE UNIVERSITE, ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (APHP)
    Inventors: Marie-Caroline Dieu-Nosjean, Wolf Herdman Fridman, Catherine Sautes-Fridman, Priyanka Devi
  • Patent number: 11376245
    Abstract: The present invention relates to compounds of formula (I) for use as peripheral NMDA receptor antagonists.
    Type: Grant
    Filed: June 13, 2017
    Date of Patent: July 5, 2022
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE PARIS SUD, ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS (APHP), HOPITAL MARIE LANNELONGUE
    Inventors: Sylvia Cohen-Kaminsky, Marc Humbert, Sebastien Dumas, Gilles Bru-Mercier, Samir Messaoudi, Jean-Daniel Brion, Mouad Alami, Gilles Galvani
  • Publication number: 20220160716
    Abstract: A compound of formula (I): wherein R1 is a (C1-C4) alkyl group, or a (C3-C6) cycloalkyl group, R2 is a phenyl or a substituted phenyl with one to three groups, with the proviso that when R2 is a phenyl then R1 is a (C3-C6) cycloalkyl group, or anyone of its pharmaceutically acceptable salt. Also, the compound of formula (I) as medicament for treating rare biliary diseases such as intrahepatic cholestatic diseases. A compound of formula (I): wherein R1 is a (C1-C4) alkyl group, or a (C3-C6) cycloalkyl group, R2 is a phenyl or a substituted phenyl with one to three groups, with the proviso that when R2 is a phenyl then R1 is a (C3-C6) cycloalkyl group, or anyone of its pharmaceutically acceptable salt. Also, the compound of formula (I) as medicament for treating rare biliary diseases such as intrahepatic cholestatic diseases.
    Type: Application
    Filed: March 20, 2020
    Publication date: May 26, 2022
    Applicants: SORBONNE UNIVERSITE, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), APHP (ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS), MANROS THERAPEUTICS
    Inventors: Thomas FALGUIERES, Virginie VAUTHIER, Laurent MEIJER, Nassima OUMATA
  • Patent number: 11300569
    Abstract: The present invention relates to the prognosis of the outcome of a cancer in a patient, which prognosis is based on the quantification of one or several biological markers that are indicative of the presence of, or alternatively the level of, the adaptive immune response of said patient against said cancer.
    Type: Grant
    Filed: December 14, 2018
    Date of Patent: April 12, 2022
    Assignees: ISERM (Institut National de la Santé et de la Recherche Médicale), Université Paris Descartes, Assistance Publique-Hôpitaux de Paris (APHP)
    Inventors: Jerome Galon, Franck Pages, Wolf-Herman Fridman
  • Publication number: 20220079507
    Abstract: A system to measure and monitor neurodegeneration of a subject, which includes: an acquisition module configured to acquire electroencephalographic signals with multiple EEG channels from a subject perceptually isolated; a calculation module configured to extract at least one EEG metric representative of neurodegeneration; and an evaluation module configured to evaluate the at least one EEG metric and extract a neurodegeneration index.
    Type: Application
    Filed: December 20, 2019
    Publication date: March 17, 2022
    Applicants: ICM (INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE), INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, APHP (ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS), SORBONNE UNIVERSITÉ
    Inventors: Stephane EPELBAUM, Sinead GAUBERT, Federico RAIMONDO, Jacobo D SITT, Lionel NACCACHE
  • Patent number: 11261445
    Abstract: Cystic fibrosis (CF) is a genetic disease caused by mutations in the gene encoding the 5 CFTR Cl— channel and affects several organs, but the most severe consequences are observed in the lung. The inventors have now instigated the combination of Orkambi® and ANO1 TSB (SEQ ID NO:1) and show that said combination increases mucociliary clearance and chloride channel activity. Thus the combination represents an alternative treatment for CF subjects.
    Type: Grant
    Filed: October 16, 2018
    Date of Patent: March 1, 2022
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), SORBONNE UNIVERSITE, ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (APHP)
    Inventors: Olivier Tabary, Florence Sonneville, Harriet Corvol
  • Patent number: 11253674
    Abstract: An in-ear stimulation system including a first device configured to be worn at least partially in a first ear canal of a subject and a second device configured to be worn at least partially in a second ear canal of the subject. Each of the first device and the second device includes: at least one in-ear active electrode configured to receive a bio-signal and at least one in-ear reference electrode configured to receive a bio-signal; at least one stimulation device configured for emitting at least one electrical or sensory stimulus; and an electronic system configured to detect at least one bio-signal pattern from the bio-signals measured from the electrodes.
    Type: Grant
    Filed: January 19, 2018
    Date of Patent: February 22, 2022
    Assignees: ICM (INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE, APHP (ASSISTANCE PUBLIQUE—HÔPITAUX DE PARIS), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), SORBONNE UNIVERSITE, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MEDICALE)
    Inventors: Michel Le Van Quyen, Alexis Genin, Alexis Steiner, Mario Valderrama, Miguel Navarrete
  • Patent number: 11242564
    Abstract: The present invention relates to a method for predicting the survival time of a patient suffering from a solid cancer comprising i) determining in a tumor sample obtained from the patient the gene expression level of at least 7 genes selected from the group consisting of CCR2, CD3D, CD3E, CD3G, CD8A, CXCL10, CXCL11, GZMA, GZMB, GZMK, GZMM, IL15, IRF1, PRF1, STAT1, CD69, ICOS, CXCR3, STAT4, CCL2, and TBX21, ii) comparing every expression level determined at step i) with their predetermined reference value and iii) providing a good prognosis when all expression levels determined at step i) are higher than their predetermined reference values, or providing a bad prognosis when all expression levels determined at step i) are lower than their predetermined reference values or providing an intermediate prognosis when at least one expression level determined value is higher than its predetermined value. The method is also particularly suitable for predicting the responsiveness of the patient to a treatment.
    Type: Grant
    Filed: July 12, 2013
    Date of Patent: February 8, 2022
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE DE PARIS, ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (APHP)
    Inventors: Jerome Galon, Franck Pages, Bernard Mlecnik, Gabriela Bindea
  • Patent number: 11231422
    Abstract: Plasma levels of different sub-populations of microvesicles (endothelial, leukocyte, platelet and hepatocyte) were measured by flow cytometry or ELISA/filtration on blood samples from 125 patients with cirrhosis, for which 36 of them were diagnosed with HCC at inclusion. The inventors show that the levels of microvesicles of endothelial origin (CD62E+) could predict the occurrence of HCC in patients with cirrhosis. Therefore the present invention relates to a method for determining whether a patient suffering from cirrhosis is at risk of having or developing hepatocellular carcinoma comprising determining the level of endothelial-derived microvesicles (e.g. by flow cytometry) in a blood sample obtained from the patient.
    Type: Grant
    Filed: March 20, 2018
    Date of Patent: January 25, 2022
    Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale), Université Paris Descartes, Assistance Publique Hôpitaux de Paris (APHP), UniversitéParis Diderot—Paris 7
    Inventors: Pierre-Emmanuel Rautou, Chantal Boulanger-Robert
  • Publication number: 20210315507
    Abstract: A method for the generation of a consciousness indicator for a non-communicating subject, including generating a sensory stimulation involving at least one of the five senses, the sensory stimulation having multiple consecutive stimuli including at least a first stimulus and a second stimulus relating to the same sense and different from one another, measuring an electrocardiographic signal of the subject during the generation of the sensory stimulation, extracting at least one EKG feature from the electrocardiographic signal associated to cognitive processes and generating a consciousness indicator using the EKG features as input of a classifier.
    Type: Application
    Filed: September 11, 2019
    Publication date: October 14, 2021
    Applicants: ICM (INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE), INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, APHP (ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS), SORBONNE UNIVERSITÉ
    Inventors: Federico RAIMONDO, Jacobo D SITT, Lionel NACCACHE, Diego FERNANDEZ SLEZAK
  • Patent number: 11085032
    Abstract: The present invention relates to mutated factor (FX) polypeptides and uses thereof for the treatment of haemophilia. In particular, the present invention relates to a mutated factor X (FX) polypeptide which comprises a heavy chain wherein at least one amino acid residue at position 401 or 408 is mutated.
    Type: Grant
    Filed: April 13, 2020
    Date of Patent: August 10, 2021
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE PARIS DIDEROT—PARIS 7, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITA DI PERUGIA, AMERICAN UNIVERSITY OF BEIRUT, ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (APHP)
    Inventors: Olivier Christophe, Cecile Denis, Peter Lenting
  • Patent number: 11077139
    Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of acute myeloid leukemia. In particular, the present invention relates to a method for treating NPM-1-driven acute myeloid leukemia (AML) in a subject in need thereof comprising administering the subject with a therapeutically effective amount of at least one arsenic compound and with a therapeutically effective amount of at least one retinoid.
    Type: Grant
    Filed: December 30, 2014
    Date of Patent: August 3, 2021
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE PARIS DIDEROT—PARIS 7, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITA DI PERUGIA, AMERICAN UNIVERSITY OF BEIRUT, ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (APHP)
    Inventors: Hugues De The, Ali Bazarbachi, Hiba El Hajj, Maria Paula Martelli, Brunangelo Falini
  • Patent number: 11065230
    Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of systemic mastocytosis. The inventors showed the effect of KPT-251 treatment on SCF-dependent human Mast cell (MC) line without KIT mutation (WT ROSA) and on two factor-independent MC lines with KIT mutations : ROSA ? 417-419 insY and ROSA D816V. KPT is a Selective Inhibitor of Nuclear Export (SINE) that specifically inhibits the activity of the exportin-1 (XPO1). KPT-251 treatment induces minimal toxicity in non-cancerous hematopoietic cells both in vitro and in vivo. In particular, the present invention relates a method of treating systemic mastocytosis in patient in need thereof comprising administering to the patient a therapeutically effective amount of a XPO1 inhibitor.
    Type: Grant
    Filed: September 15, 2017
    Date of Patent: July 20, 2021
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), FONDATION IMAGINE, UNIVERSITE PARIS DESCARTES, ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS (APHP), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE DE CAEN NORMANDIE, CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE CAEN
    Inventors: Olivier Hermine, Flavia Guillem, Gandhi Damaj, Sophia Ladraa
  • Patent number: 11065238
    Abstract: The present invention relates to inhibitors of gangliosides metabolism for treating motor neuron diseases, in particular hereditary spastic paraplegias.
    Type: Grant
    Filed: November 3, 2017
    Date of Patent: July 20, 2021
    Assignees: ICM (INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE), SORBONNE UNIVERSITE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE, APHP (ASSISTANCE PUBLIQUE—HÔPITAUX DE PARIS), ÉCOLE PRATIQUE DES HAUTES ÉTUDES
    Inventors: Frédéric Darios, Giovanni Stevanin, Fanny Mochel, Julien Branchu, Maxime Boutry
  • Patent number: 11060147
    Abstract: The present invention relates to methods for predicting acute severe colitis treatment response. Currently, there is no biomarker of drug response. The present invention provides the first prediction tool for responses to first- and second-line treatments in acute severe ulcerative colitis. Putative mRNA targets of dysregulated microRNAs were identified from patient biopsies. One classifier of fifteen colonic microRNAs plus five biological values at admission were identified with a prediction accuracy of 96.6% for discriminating responders from non-responders to steroids. Using a similar method, 6 and 4 mucosal microRNA-based algorithms were identified to classify responders from non-responders to infliximab and cyclosporine.
    Type: Grant
    Filed: June 14, 2017
    Date of Patent: July 13, 2021
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE DE PARIS, ASSISTANCE PUBLIQUE-HOPPITAUX DE PARIS (APHP), UNIVERSITE DE BORDEAUX, CHU DE BORDEAUX, UNIVERSITE PARIS XIII PARIS-NORD
    Inventors: Eric Ogier-Denis, Xavier Treton, Yoram Bouhnik, Ian Morilla, David Laharie, Gilles Wainrib, Mathieu Uzzan
  • Patent number: 11041147
    Abstract: The present invention relates to a bacteriophage strain capable of producing a lytic infection in the Escherichia coli ST131-025b:H4 clone. The burden of ST131-025b:H4 Escherichia coli clonal complex in human community and hospital-acquired infections is increasing worldwide, going along with a worrying and growing resistance to betalactams and fluoroquinolones. Bacteriophage LM33_P1 infects exclusively (100% specificity) 025b E. coli strains with 70% coverage on the two major antibiotic resistant pandemic clonal complexes ST131-025b:H4 and ST69-025b. The inventors evaluated the in vivo activity of bacteriophage LM33_P1 using three different extraintestinal virulence murine models and showed that it infects bacteria in several organs.
    Type: Grant
    Filed: April 12, 2017
    Date of Patent: June 22, 2021
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE, ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS (APHP), UNIVERSITÉ PARIS DIDEROT—PARIS 7, UNIVERSITÉ PARIS XIII PARIS-NORD
    Inventors: Jean-Damien Ricard, Olivier Clermont, Laurent Debarbieux, Erick Denamur, Nicolas Dufour
  • Publication number: 20210093247
    Abstract: A computer-implemented method for detecting pathological brain activity patterns from a scalp electroencephalographic signal, the method including the steps of obtaining (A) an electroencephalographic signal as a function of multiple channels and time; identifying (C), for each channel, the zero-crossings of the electroencephalographic signal over a fixed threshold; generating a zero-crossing representation of at least a segment of the obtained electroencephalographic signal with the identified zero-crossings; obtaining (D) a reference family of real functions of time and channels from a zero-crossing statistical analysis of zero-crossing representation of pre-recorded electroencephalographic signals; calculating (E) a matching score by comparing the zero-crossing representation of a segment of the electroencephalographic signal with at least one reference function from the reference family of functions; and computing the matching score as a function of time by sliding the at least one reference function from
    Type: Application
    Filed: March 30, 2018
    Publication date: April 1, 2021
    Applicants: BIOSERENITY, ICM (INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE), APHP (ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), SORBONNE UNIVERSITE
    Inventors: Jan PYRZOWSKI, Michel LE VAN QUYEN, Jean-Eudes LE DOUGET
  • Patent number: 10961585
    Abstract: This document provides methods and materials related to treating a disease. For example, this document provides methods for treating a subject's disease based on identifying the risk of progressive multifocal leukoencephalopathy PML using a genetic test.
    Type: Grant
    Filed: August 15, 2019
    Date of Patent: March 30, 2021
    Assignees: PML Screening, LLC, The Université Paris-Suclay, The Assistance Publique—Hopitaux de Paris (APHP), The Institut National de la Sante et de la Recherche Medicale
    Inventors: Eli Hatchwell, Peggy S. Eis, Edward B. Smith, III, Yassine Taoufik